Graft-versus-host disease: How to translate new insights into new therapeutic strategies

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 12, 2004, Pages 815-825

  Devetten, Marcel P ^a   Vose, Julie M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Alemtuzumab; ATG; Extracorporeal photophoresis; Graft versus host disease; MMR; Pento statin; Sirolimus; Stem cell transplant; T cell depletion

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATURAL KILLER CELL RECEPTOR NKG2D; PENTOSTATIN; RAPAMYCIN; RECEPTOR BLOCKING AGENT; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; DRUG MECHANISM; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; INFECTION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAXIMUM TOLERATED DOSE; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; PATHOPHYSIOLOGY; PUVA; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFUSION; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES;

EID: 10344252879     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.10.005     Document Type: Review

References (76)

1. J. Murphy The effect of adult chicken organ graft on the chick embryo J Exp Med 24 1916 1-6
2. R. Billingham L. Brent Quantitative studies on tissue transplantation immunity. IV. Induction of tolerance in newborn mice and studies on the phenomenon of runt disease Philos Trans R Soc Lond 242 1959 439-477
3. R.E. Billingham The biology of graft-versus-host reactions Harvey Lect 62 1966 21-78
4. C.Q. Xun J.S. Thompson C.D. Jennings et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice Blood 83 1994 2360-2367
5. W.D. Shlomchik M.S. Couzens C.B. Tang et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells Science 285 1999 412-415
6. T. Teshima R. Ordemann P. Reddy et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium Nat Med 8 2002 575-581
7. C.C. Hofmeister A. Quinn K.R. Cooke et al. Graft-versus-host disease of the skin: Life and death on the epidermal edge Biol Blood Marrow Transplant 10 2004 366-372
8. G.R. Hill J.L. Ferrara The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation Blood 95 2000 2754-2759
9. F. Paris Z. Fuks A. Kang et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 293 2001 293-297
10. M.T. Lin B. Storer P.J. Martin et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation N Engl J Med 349 2003 2201-2210
11. L.J. Keen T.E. DeFor J.L. Bidwell et al. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation Blood 103 2004 3599-3602
12. T. Kamradt N.A. Mitchison Tolerance and autoimmunity N Engl J Med 344 2001 655-664
13. X.C. Li T.B. Strom L.A. Turka et al. T cell death and transplantation tolerance Immunity 14 2001 407-416
14. P.A. Taylor C.J. Lees B.R. Blazar The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality Blood 99 2002 3493-3499
15. M. Stanzani S.L. Martins R.M. Saliba et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans Blood 103 2004 1140-1146
16. Y. Miura C.J. Thoburn E.C. Bright et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease Blood 104 2004 2187-2193
17. M. Theobald T. Nierle D. Bunjes et al. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings N Engl J Med 327 1992 1613-1617
18. M.J. Smyth Y. Hayakawa K. Takeda et al. New aspects of natural-killer-cell surveillance and therapy of cancer Nat Rev Cancer 2 2002 850-861
19. L. Ruggeri M. Capanni E. Urbani et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097-2100
20. D.R. Couriel R.M. Saliba S. Giralt et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Biol Blood Marrow Transplant 10 2004 178-185
21. M. Mielcarek P.J. Martin W. Leisenring et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 2003 756-762
22. E. Holler H.J. Kolb J. Mittermuller et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F) Blood 86 1995 890-899
23. D. Blaise D. Olive M. Hirn et al. Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): A feasibility trial in 15 patients Bone Marrow Transplant 8 1991 105-111
24. C. Anasetti P.J. Martin R. Storb et al. Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3 Bone Marrow Transplant 7 1991 375-381
25. K.B. Miller T.F. Roberts G. Chan et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease Bone Marrow Transplant 33 2004 881-889
26. P.D. Kottaridis D.W. Milligan R. Chopra et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation Blood 96 2000 2419-2425
27. A.Y. Ho A. Pagliuca M. Kenyon et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Blood 104 2004 1616-1623
28. P. McSweeney S. Abhyankar F. Petersen et al. Tacrolimus and mycophenolate mofetil for GVHD prevention after unrelated donor transplants Blood 102 2003 717a (abstr.)
29. E. Meijer J.J. Cornelissen B. Lowenberg et al. Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: A dose-finding study Exp Hematol 31 2003 1026-1030
30. R. Nash L. Johnston P. Parker et al. A phase I/II study of mycophenolate mofetil (MMF) in combination with cyclosporine (CSP) for prophylaxis of graft versus host disease (GVHD) after myeloablative conditioning and allogeneic hematopoietic stem cell transplantation (HCT): Dose escalation of MMF Blood 102 2003 240a (abstr)
31. J.H. Antin H.T. Kim C. Cutler et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation Blood 102 2003 1601-1605
32. C. Cutler H.T. Kim E. Hochberg et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation Biol Blood Marrow Transplant 10 2004 328-336
33. P.L. McCarthy Jr S. Abhyankar S. Neben et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease Blood 78 1991 1915-1918
34. J.H. Antin D. Weisdorf D. Neuberg et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: Results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation Blood 100 2002 3479-3482
35. P.J. Martin J. Pei T. Gooley et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation Biol Blood Marrow Transplant 10 2004 552-560
36. G. Gorgun K.B. Miller F.M. Foss Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease Blood 100 2002 941-947
37. J.G. Gribben E.C. Guinan V.A. Boussiotis et al. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool Blood 87 1996 4887-4893
38. E.C. Guinan V.A. Boussiotis D. Neuberg et al. Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med 340 1999 1704-1714
39. P. Klangsinsirikul G.I. Carter J.L. Byrne et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution Blood 99 2002 2586-2591
40. S. Chakrabarti D. MacDonald G. Hale et al. T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival Br J Haematol 121 2003 109-118
41. R.E. Curtis L.B. Travis P.A. Rowlings et al. Risk of lymphoproliferative disorders after bone marrow transplantatio: A multi-institutional study Blood 94 1999 2208-2216
42. P.D. Kottaridis D.W. Milligan R. Chopra et al. In vivo Campath-1H prevents GvHD following nonmyeloablative stem-cell transplantation Cytotherapy 3 2001 197-201
43. S. Chakrabarti I. Avivi S. Mackinnon et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: High incidence but low mortality Br J Haematol 119 2002 1125-1132
44. S. Chakrabarti S. Mackinnon R. Chopra et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution Blood 99 2002 4357-4363
45. A.C. Allison E.M. Eugui Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF) Clin Transplant 10 1996 77-84
46. B.M. Sandmaier P. McSweeney C. Yu et al. Nonmyeloablative transplants: preclinical and clinical results Semin Oncol 27 2000 78-81
47. M. Bornhauser U. Schuler G. Porksen et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation Transplantation 67 1999 499-504
48. P. McSweeney S. Abhyankar J. Foran et al. Favorable early transplant outcomes using tacrolimus and mycophenolate mofetil for GVHD prevention after matched sibling allografting Blood 102 2003 717a (abstr.)
49. S.N. Sehgal Sirolimus: Its discovery, biological properties, and mechanism of action Transplant Proc 35 3 suppl 2003 7S-14S
50. B.D. Kahan S. Gibbons N. Tejpal et al. Synergistic effect of the rapamycin-cyclosporine combination: Median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays Transplant Proc 23 1991 1090-1091
51. R.T. Mitsuyasu R.E. Champlin R.P. Gale et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial Ann Intern Med 105 1986 20-26
52. T. de Witte J. Hoogenhout B. de Pauw et al. Depletion of donor lymphocytes by counterflow centrifugation successfully prevents acute graft-versus-host disease in matched allogeneic marrow transplantation Blood 67 1986 1302-1308
53. M. Rachamim J. Gan H. Segall et al. Tolerance induction by 'megadose' hematopoietic transplants: Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture Transplantation 65 1998 1386-1393
54. F. Aversa A. Terenzi R. Felicini et al. Haploidentical stem cell transplantation for acute leukemia Int J Hematol 76 suppl 1 2002 165-168
55. L. Ruggeri M. Capanni M. Casucci et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood 94 1999 333-339
56. R. Korngold J. Sprent Lethal graft-versus-host disease across minor histocompatibility barriers in mice Clin Haematol 12 1983 681-693
57. J. Wagner J. Thompson S. Carter et al. Impact of graft-versus-host disease (GVHD) prophylaxis on 3-year disease-free survival (DFS): results of a multi-center, randomized phase II-III trial comparing T cell depletion/cyclosporine (TCD) and methotrexate/cyclosporine (M/C) in 410 recipients of unrelated donor bone marrow Blood 100 2002 75a (abstr.)
58. M. Remberger B. Storer O. Ringden et al. Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors Bone Marrow Transplant 29 2002 391-397
59. P. Duggan K. Booth A. Chaudhry et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: A matched pair analysis Bone Marrow Transplant 30 2002 681-686
60. A. Bacigalupo T. Lamparelli P. Bruzzi et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) Blood 98 2001 2942-2947
61. L. Genestier S. Fournel M. Flacher et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins Blood 91 1998 2360-2368
62. M.L. MacMillan D.J. Weisdorf J.E. Wagner et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems Biol Blood Marrow Transplant 8 2002 387-394
63. S. Lee B. Dorken C.A. Schmitt Extracorporeal photopheresis in graft-versus-host disease ultraviolet radiation mediates: T cell senescence in vivo Transplantation 78 2004 484-485
64. J. Uberti L. Ayash J. Levine et al. Phase I/II trial on the use of etanercept (Enbrel) and soluMedrol as primary treatment for acute graft-vs-host disease (aGVHD) Blood 102 2003 243a [abstr.]
65. D. Couriel R. Saliba K. Hicks et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD Blood 104 2004 649-654
66. V.T. Ho D. Zahrieh E. Hochberg et al. Safety and efficacy of denileukin diftitox in patients with steroid refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Blood 104 2004 1224-1226
67. J. Bolanos-Meade D. Jacobson J. Margolis et al. Pentostatin in steroid refractory acute graft versus host disease Blood 100 2002 420a (abstr.)
68. S.J. Lee D. Zahrieh E. Agura et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: Results of a randomized trial Blood 104 2004 1559-1564
69. H. Khoury A. Kashyap D.R. Adkins et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin Bone Marrow Transplant 27 2001 1059-1064
70. S. Arai J. Margolis M. Zahurak et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment Biol Blood Marrow Transplant 8 2002 155-160
71. D. Jacobsohn J. Margolis A. Chen et al. Pentostatin: A promising treatment for refractory chronic GVHD Blood 98 2001 399a (abstr.)
72. J.D. Goldberg D.A. Jacobsohn J. Margolis et al. Pentostatin for the treatment of chronic graft-versus-host disease in children J Pediatr Hematol Oncol 25 2003 584-588
73. H.T. Greinix B. Volc-Platzer P. Kalhs et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study Blood 96 2000 2426-2431
74. R. Dall'Amico C. Messina Extracorporeal photochemotherapy for the treatment of graft-versus-host disease Ther Apher 6 2002 296-304
75. K. Le Blanc L. Tammik B. Sundberg et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex Scand J Immunol 57 2003 11-20
76. K. Le Blanc I. Rasmusson B. Sundberg et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells Lancet 363 2004 1439-1441